Cannabichromenic acid

Cannabichromenic acid
Product Name Cannabichromenic acid
CAS No.: 185505-15-1
Catalog No.: CFN91611
Molecular Formula: C22H30O4
Molecular Weight: 358.47 g/mol
Purity: >=98%
Type of Compound: Phenols
Physical Desc.: Powder
Source: The herbs of Cannabis sativa.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price:
Cannabichromenic acid is a new antibiotic active against gram-positive bacteria, including MRSA.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Int J Mol Med.2016, 37(2):501-8
  • J Nat Med.2020, 74(3):550-560.
  • Food Sci Biotechnol.2021, 30(2):217-226.
  • Biosci. Rep.2020, 10.1024
  • Pharm Biol.2021, 59(1):134-145.
  • Drug Des Devel Ther.2023, 17:2461-2479.
  • Molecules 2022, 27(3),1047.
  • Molecules 2021, 26(4),1092.
  • Journal of Natural Remedies2024, 24(3):555C575.
  • Phytomedicine.2022, 96:153877.
  • Cannabigerovarinic acid

    Catalog No: CFN91610
    CAS No: 64924-07-8
    Price: Inquiry(manager@chemfaces.com)
    Cannabigerol

    Catalog No: CFN98287
    CAS No: 25654-31-3
    Price: $338/10mg
    Cannabichromene

    Catalog No: CFN98039
    CAS No: 20675-51-8
    Price: $318/5mg
    Cannabichromevarinic acid

    Catalog No: CFN91609
    CAS No: 64898-02-8
    Price: Inquiry(manager@chemfaces.com)
    Cannabichromenic acid

    Catalog No: CFN91611
    CAS No: 185505-15-1
    Price: Inquiry(manager@chemfaces.com)
    Atractylochromene

    Catalog No: CFN95162
    CAS No: 203443-33-8
    Price: $318/10mg
    Denudaquinol

    Catalog No: CFN91935
    CAS No: 1189105-40-5
    Price: Inquiry(manager@chemfaces.com)
    Nervogenic acid

    Catalog No: CFN99828
    CAS No: 17622-86-5
    Price: Inquiry(manager@chemfaces.com)
    4-Hydroxy-3-(3-methyl-2-butenoyl)-5-(3-methyl-2-butenyl)benzoic acid

    Catalog No: CFN99652
    CAS No: 155051-85-7
    Price: Inquiry(manager@chemfaces.com)
    2,2-Dimethyl-8-prenylchromene 6-carboxylic acid

    Catalog No: CFN99633
    CAS No: 151731-50-9
    Price: Inquiry(manager@chemfaces.com)
    Antibiotics (Basel) . 2020 Aug 16;9(8):523.
    Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus[Pubmed: 32824356]
    Methicillin-resistant Staphylococcus aureus (MRSA) has proven to be an imminent threat to public health, intensifying the need for novel therapeutics. Previous evidence suggests that cannabinoids harbour potent antibacterial activity. In this study, a group of previously inaccessible phytocannabinoids and synthetic analogues were examined for potential antibacterial activity. The minimum inhibitory concentrations and dynamics of bacterial inhibition, determined through resazurin reduction and time-kill assays, revealed the potent antibacterial activity of the phytocannabinoids against gram-positive antibiotic-resistant bacterial species, including MRSA. One phytocannabinoid, Cannabichromenic acid (CBCA), demonstrated faster and more potent bactericidal activity than vancomycin, the currently recommended antibiotic for the treatment of MRSA infections. Such bactericidal activity was sustained against low-and high-dose inoculums as well as exponential- and stationary-phase MRSA cells. Further, mammalian cell viability was maintained in the presence of CBCA. Finally, microscopic evaluation suggests that CBCA may function through the degradation of the bacterial lipid membrane and alteration of the bacterial nucleoid. The results of the current study provide encouraging evidence that cannabinoids may serve as a previously unrecognised resource for the generation of novel antibiotics active against MRSA.
    J Nat Prod. 2019 Nov 22;82(11):3047-3055.
    Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome[Pubmed: 31686510]
    Cannabis sativa produces a complex mixture of many bioactive molecules including terpenophenolic compounds known as phytocannabinoids. Phytocannabinoids come in neutral forms (e.g., Δ9-tetrahydrocannabinol, THC; cannabidiol, CBD; etc.) or as acid precursors, which are dominant in the plant (e.g., Δ9-tetrahydrocannabinolic acid, THCA; cannabidiolic acid, CBDA; etc.). There is increasing interest in unlocking the therapeutic applications of the phytocannabinoid acids; however, the present understanding of the basic pharmacology of phytocannabinoid acids is limited. Herein the brain and plasma pharmacokinetic profiles of CBDA, THCA, Cannabichromenic acid (CBCA), cannabidivarinic acid (CBDVA), cannabigerolic acid (CBGA), and cannabigerovarinic acid (CBGVA) were examined following intraperitoneal administration in mice. Next it was examined whether CBDA was anticonvulsant in a mouse model of Dravet syndrome (Scn1aRX/+ mice). All the phytocannabinoid acids investigated were rapidly absorbed with plasma tmax values of between 15 and 45 min and had relatively short half-lives (<4 h). The brain-plasma ratios for the acids were very low at ≤0.04. However, when CBDA was administered in an alternate Tween 80-based vehicle, it exhibited a brain-plasma ratio of 1.9. The anticonvulsant potential of CBDA was examined using this vehicle, and it was found that CBDA significantly increased the temperature threshold at which the Scn1aRX/+ mice had a generalized tonic-clonic seizure.
    Gymnoside III

    Catalog No: CFN95033
    CAS No: 899430-03-6
    Price: $238/10mg
    Carasinol B

    Catalog No: CFN95042
    CAS No: 777857-86-0
    Price: $333/5mg
    Quercetin 3-O-beta-(6''-p-coumaroyl)glucopyranosyl(1->2)-alpha-L-rhamnopyranoside

    Catalog No: CFN95088
    CAS No: 143061-65-8
    Price: $338/10mg
    Kaempferol 3-O-beta-(6''-p-coumaroyl)glucopyranosyl(1->2)-alpha-L-rhamnopyranoside

    Catalog No: CFN95089
    CAS No: 111957-48-3
    Price: $338/10mg
    Polygalasaponin XLIX

    Catalog No: CFN95117
    CAS No: 1033593-12-2
    Price: $318/10mg
    Henricine

    Catalog No: CFN95244
    CAS No: 107783-46-0
    Price: $413/5mg
    Safflospermidine A

    Catalog No: CFN95255
    CAS No: 1111082-13-3
    Price: $413/5mg
    13(S)-Hydroxyoctadeca-9(Z),11(E)-dienoic acid (13-HODE)

    Catalog No: CFN95307
    CAS No: 18104-45-5
    Price: $318/10mg
    Platycodin J

    Catalog No: CFN95395
    CAS No: 1325614-80-9
    Price: $318/5mg
    Ganoderic acid J

    Catalog No: CFN95516
    CAS No: 100440-26-4
    Price: $318/10mg